33 results
Thumbnail

D2.436 - Anti-tumoral effect of hydatic cyst fluid in a cell-derived breast cancer xenograft model

Thumbnail

D2.439 - Corticosteroids promoted organoid formation and differentiation of SSEA-1+ lung stem/progenitor cells

Thumbnail

D2.445 - Systemic Nitric Oxide: a promising inflammatory biomarker for early detection, prognosis, and monitoring of patients with colon cancer

Thumbnail

D2.437 - Human memory CD4+T cells induce hyperresponsiveness in mast cells

Thumbnail

D2.440 - From Steroid Dependence to Remission: Anti–IL-5 Therapy in Gastrointestinal Hypereosinophilic Syndrome

Thumbnail

D2.441 - Association of High Sensitive-C-reactive Protein with Left Ventricle Remodeling in Type 1 Diabetes Mellitus

Thumbnail

D2.442 - AAV-Mediated IL-10 Gene Delivery Enhances Antitumor Immunity While Preserving Immune Tolerance in Hepatocellular Carcinoma

Thumbnail

D2.443 - Serum Zonulin Reflects Disease Activity and Psychiatric Burden in Hereditary Angioedema

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut

Thumbnail

D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study